Clay Siegall is a committed, experienced scientist who is passionate about fining effective targeted treatments for cancer. He is also a savvy businessman that understands the importance of keeping his company profitable. Since founding the Bothell, Washington based biotechnology company Seattle Genetics in 1998 and serving as its CEO, Dr. Siegall has excelled at doing both. Seattle Genetics has created groundbreaking cancer treatments that are used worldwide and Dr. Siegall has helped the company to rake in $1.2 billion from public and private sources.
Inspired to seek better cancer treatments as a teenager after seeing his father battle the disease, he graduated from the University of Maryland with a B.S. in Zoology and went on to George Washington University where he earned a doctorate in Genetics. Since then, Dr. Siegall has worked with Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute as well as the National Institutes of Health and other top organizations involved in researching effective cancer treatments.
Dr. Clay Siegall has also done so well in making sure that Seattle Genetics functions as a profitable business he was voted ‘Entrepreneur of the Year’ in 2012 by Ernst & Young. He has formed lucrative partnerships with major pharmaceutical companies to market ADCETRIS, an anti-body-based cancer therapy developed by Seattle Genetics which gained FDA approval in 2011. Plus the company has dozens of other promising drugs in its development pipeline. Dr. Siegall has also generated money for the company through a very successful IPO in 2001 and has the company positioned to be profitable for many years to come.
In addition to his research and business efforts, Dr. Clay Siegall holds 15 patents and has published numerous articles on cancer research and treatment. He is also on the board of directors of several biotechnology companies. During his decades in the cancer research and treatment field, Clay Siegall has managed to handle the delicate balancing act between finding effective cancer treatments and running a profitable biotechnology company with aplomb. He has built Seattle Genetics on a foundation of solid scientific research and helped to provide quality cancer treatment for countless patients.